Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
Vir Biotechnology, Inc. (VIR) Q3 2025 Earnings Call Transcript
09:41pm, Wednesday, 05'th Nov 2025
Vir Biotechnology, Inc. ( VIR ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jason O'Byrne - Executive VP & CFO Marianne De Backer - CEO & Director Mark Eisner - Executive V
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
06:46pm, Wednesday, 05'th Nov 2025
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $1.56 per share a year ago.
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2025 Financial Results
04:05pm, Wednesday, 05'th Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the third quarter ended September 30, 2025. "Our third quart
Vir Biotechnology Announces Completion of Enrollment in ECLIPSE 1 Phase 3 Trial for Chronic Hepatitis Delta
08:00am, Monday, 03'rd Nov 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the completion of enrollment for ECLIPSE 1, a Phase 3 trial evaluating the safety and efficacy of the combination
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
04:05pm, Wednesday, 22'nd Oct 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended Septemb
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Company's Phase 1 clinical trial evaluating VIR-5500 in com
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
10:30am, Thursday, 09'th Oct 2025
Vir Biotechnology (VIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
Vir Biotechnology to Present Week 48 SOLSTICE Clinical Results in Hepatitis Delta at AASLD's The Liver Meeting® 2025
08:00am, Tuesday, 07'th Oct 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present Week 48 endpoint results from the SOLSTICE Phase 2 clinical study evaluating tobevibart a
Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
01:15pm, Tuesday, 16'th Sep 2025
Vir Biotechnology, Inc. (NASDAQ:VIR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 4:05 PM EDT Company Participants Marianne De Backer - CEO & Director Mark Eisner - Execu
BofA upgrades Vir Biotechnology to Buy on underappreciated HDV opportunity
06:12am, Wednesday, 27'th Aug 2025
As previously reported, BofA analyst Alec Stranahan upgraded Vir Biotechnology to Buy from Neutral with a price target of $14, up from $12, arguing that the market is underestimating the potential for
Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
04:05pm, Monday, 25'th Aug 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Mo
Vir (VIR) Q2 Revenue Drops 61%
12:32am, Thursday, 07'th Aug 2025
Vir Biotechnology (VIR -0.59%), a clinical-stage biotech focused on infectious diseases and immuno-oncology, reported results on August 6, 2025. The company announced a net loss per share of $(0.80) (
Vir Biotechnology, Inc. (VIR) Q2 2025 Earnings Call Transcript
11:01pm, Wednesday, 06'th Aug 2025
Vir Biotechnology, Inc. (NASDAQ:VIR ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Jason O'Byrne - Executive VP & CFO Marianne De Backer - CEO & Director Mark D. Eis
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates
07:51pm, Wednesday, 06'th Aug 2025
Vir Biotechnology, Inc. (VIR) came out with a quarterly loss of $0.8 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $1.02 per share a year ago.
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results
04:05pm, Wednesday, 06'th Aug 2025
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2025. “We achieved sever
